Received Jul 25, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Pimple like small bump on her head; Patient has not yet received the second dose; This non-serious case was reported by a consumer via call center representative and described the occurrence of pimple-like rash in an adult female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. In DEC-2024, the patient received the 1st dose of Shingrix. The patient did not receive the 2nd dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pimple-like rash (Verbatim: Pimple like small bump on her head) and incomplete course of vaccination (Verbatim: Patient has not yet received the second dose). The outcome of the pimple-like rash was resolved and the outcome of the incomplete course of vaccination was not applicable. It was unknown if the reporter considered the pimple-like rash to be related to Shingrix. It was unknown if the company considered the pimple-like rash to be related to Shingrix. Additional Information: GSK Receipt Date: 07-JUL-2025 The reporter was an adult female patient. The patient received the first dose of Shingrix in December 2024. To date, the patient had not yet received the second dose which led to incomplete course of vaccination. The patient experienced a pimple like small bump on her head after receiving the first dose of Shingrix. The patient admitted that it could have been from shampoo or hair color/dye that she was using at the time.